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Available online 21 February 2017The aimof thisworkwas to rationally design and characterize nanocapsules (NCs) composedof an oily core and a
polyarginine (PARG) shell, intended for oral peptide delivery. The cationic polyaminoacid, PARG, and the oily core
componentswere selected based on their penetration enhancing properties. Insulinwas adopted as amodel pep-
tide to assess the performance of the NCs. After screening numerous formulation variables, including different
oils and surfactants, we defined a composition consisting of oleic acid, sodium deoxycholate (SDC) and Span
80. This selected NCs composition, produced by the solvent displacement technique, exhibited the following
key features: (i) an average size of 180 nm and a low polydispersity (0.1), (ii) a high insulin association efficacy
(80–90% AE), (iii) a good colloidal stability upon incubation in simulated intestinal fluids (SIF, FaSSIF-V2, FeSSIF-
V2), and (iv) the capacity to control the release of the associated insulin for N4 h. Furthermore, using the Caco-2
model cell line, PARG nanocapsules were able to interact with the enterocytes, and reversibly modify the TEER of
the monolayer. Both cell adhesion and membrane permeabilization could account for the pronounced transport
of the NCs-associated insulin (3.54%). This improved interaction was also visualized by confocal fluorescent mi-
croscopy following oral administration of PARG nanocapsulesto mice. Finally, in vivo efficacy studies performed
in normoglycemic rats showed a significant decrease in their plasma glucose levels after treatment. In conclusion,






Oral peptide delivery1. Introduction
Peptide therapeutics has drawn increasing interest in the pharma-
ceutical market since the 1970s. Over the last decades, the regulatory
approval rate of these products has been shown to be superior to that
of small molecules, and their global value has increased from 14.1 to
25.4 billion USD from 2011 to 2018 [1]. Currently, over 500 peptide
drugs are under preclinical development, 140 are candidates in clinical
trials and about 60 commercialized products have been approved by
the FDA [2]. Due to their complex structure, these macromolecules
offer high specificity, advanced drug potency, low toxicity and less in-
teraction with other drugs when compared to small molecules. Howev-
er, because of their physicochemical properties, their delivery to the
subjects' body represents a critical challenge. In particular, thesemacro-
molecules are prone to lose their activity in a physiological environmentn open access article underand have great difficulties to cross biological barriers. Because of this, up
to date, peptide therapeutics is principally administrated via injection,
which is an easy but inconvenient way of medication.
Oral administration is the most attractive modality for the adminis-
tration of peptide drugs. However, peptides administered by this route
would have to overcome major barriers, including the harsh gastroin-
testinal environment, the mucus layer and the underlying epithelium
barrier [3]. The approaches investigated so far to improve the intestinal
absorption of peptides include the chemical modification of the peptide
molecule, the co-administration of protease inhibitors and/or perme-
ation enhancers, and the incorporation of the peptide formulation to de-
livery carriers [4,5]. A broad array of carriers including polymeric micro
and nanoparticles, silica nanoparticles, liposomes, micelles, solid lipid
nanoparticles, microemulsions, self-emulsifying drug delivery systems,
nanoemulsions and NCs have been explored for the delivery of peptide
drugs [6–8]. Among them, liver-targeted HDV-I liposomes of specific
composition [9], bioadhesive calcium phosphate nanoparticles in an en-
teric capsule [10], and silica nanoparticles [11] have reached the clinicalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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success of these delivery carriers has not been described in detail, it is
generally assumed that these carriers have the capacity to overcome
the GI barriers.
Within this frame, our laboratory has contributed with the design of
NCs consisting of an oily core surrounded by a shell made of chitosan
[12–15]. These NCs allowed us to encapsulate the peptide salmon calci-
tonin (sCT), and the resulting nanocomposition was found to facilitate
and prolong sCT absorption following oral administration. More recent-
ly, we have also explored the interaction of PARG nanocapsules based
on Miglyol® core [16] with the Caco-2 monolayer [17] and concluded
that PARGNCmay have a potential for oral delivery. Taking into account
this background information, the objective of this work was to engineer
a new composition based on PARG NCs that would endow them with
the capacity to load peptides, i.e. insulin, and to overcome the biological
barriers associated with the oral modality of administration. Hence, the
main criteria for this design were: i) efficient encapsulation and con-
trolled release of the selected peptide, i.e. insulin; ii) stability in the in-
testinal fluids, in the presence of enzymes and bile salts; iii) capacity
to diffuse across the mucus layer and, iv) capacity to interact with the
intestinal epithelium and facilitate the transport of the associated pep-
tide across it. With these criteria in mind, we performed a thoughtful
analysis of the potential ingredients to form the lipid core, and selected
oleic acid and SDC because of their permeation enhancing properties
[18–22]. Besides, SDC is known to form complexes with insulin during
the formulation process, thus improving the encapsulation of insulin
[23,24]. On the other hand, we chose polyarginine (PARG) as the mate-
rial to form the polymer shell. Finally, to facilitate the dispersion of the
oily droplets and improve the stability of the NCs in the intestinal fluids,
we selected surfactants with different HLB values, i.e. poloxamer 188
and Span®80 [25]. Once formulated, we determined the physicochem-
ical properties of theseNCs and their capacity to promote the absorption
of insulin in different in vitro and in vivo intestinal models.
2. Materials and methodology
2.1. Materials
Recombinant human insulin hexamer Insuman®(Mw5808Da)was
kindly provided by Sanofi (Paris, France). Poly-L-Arginine (Mw 26–
37 kDa) was purchased from Polypeptide Therapeutic Solutions (PTS,
Valencia, Spain). Analytical grade poloxamer 188, oleic acid, Span® 80,
SDC and Triton™ X-100 were purchased from Sigma Aldrich (St. Louis,
USA). Pharmaceutical grade poloxamer 188 was purchased from BASF
(Ludwigshafen, Germany); pharmaceutical grade oleic acid and Span®
80 were purchased from Croda (Snaith, UK); pharmaceutical grade
SDC was purchased from New Zealand Pharmaceuticals (Palmerston
North, New Zealand). Pancreatin (8xUSP) was purchased from Biozym
(Hamburg, Germany). Sephadex® G-50 was purchased from GE
healthcare (Little Chalfont, UK). The 1,10-dioctadecyl-3,3,30,30-
tetramethylindodicarbocyanine perchlorate fluorescent dye (DiD oil,
Em 644 nm; Ex 663 nm) was obtained from Life Technologies (Eugene,
USA). Human colorectal adenocarcinoma Caco-2 cells (ATCC® HTB37
™) were purchased from American Type Culture Collection (Manassas,
VA, USA). High glucose Dulbecco's modified eagle medium (DMEM)
and non-essential amino acid (NEAA) solution were purchased from
Sigma Aldrich (St. Louis, USA), while heat inactivated fetal bovine
serum (FBS), penicillin-streptomycin solution, L-glutamine, phos-
phate-buffered saline (PBS), Dulbecco's phosphate-buffered saline
with calcium and magnesium (DPBS) were purchased from Lonza
(Basel, Switzerland). Reagents for cytotoxicity assays were MTS based
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit
(Promega, Madison, USA), LDH cytotoxicity detection kit plus (Roche,
Mannheim, Germany) and Neutral Red based In Vitro Toxicology
Assay Kit, (Sigma Aldrich, St. Louis, USA). Ultrapurified water was ob-
tained from Millipore Milli-Q Plus water purification system(Darmstadt, Germany). HCl and NaOH solutions are purchased from
Scharlab (Barcelona, Spain). All the other chemicals were of analytical
grade.2.2. Preparation of the PARG NCs
Polyarginine based NCs were prepared by a modified solvent dis-
placement technique previously developed by our laboratory [26,27].
Different oils (oleic acid or Miglyol® 812N) and surfactants (Span®80,
Tween®80 or Labrasol®) at different concentrations were explored
for the formation of the NC's core. Finally, at the optimum condition, in-
sulin was dissolved in 0.01 N HCl (pH ~ 2.1) at a concentration of
15 mg/mL, and 0.1 mL of this solution was transferred to an organic
phase composed by 62.5 μL oleic acid, 20 mg surfactant Span®80,
4.1 mL acetone and 0.8 mL ethanol with/without 2.5 mg SDC. This or-
ganic phase was mixed using a vortex agitator (VELP Scientifica,
Usmate, Italy) and immediately poured onto 10 mL of ultrapure water
or pH 5.5 acetate/citrate buffer. In the first case, the pH of the external
aqueous phase was adjusted with 0.1 N NaOH. Alternatively, 10 mM,
20 mM, 30 mM and 50 mM pH 5.5 acetate or citrate buffer was used
to prepare the aqueous phase to ensure the desired final formulation
pH (pH 5.5). In all cases, the aqueous phase solution contained 0.05%
(w/v) PARG and 0.25% (w/v) of poloxamer 188. After magnetic stirring
for 10min, the solvents were evaporated under vacuum, decreasing the
volume of the final formulation from 15 mL to 5 mL in a rotavapor
(Heidolph Hei-VAP Advantage, Schwabach, Germany). Oleic acid-
based nanoemulsions, used as controls for some experiments, were pre-
pared by the same method without incorporating PARG.
Fluorescent NCs to be used for in vitro/in vivo studies were also pro-
duced by adding 50 μg DiD to the organic phase. The absence of dye
leakage was assessed upon incubation of the nanocapsules in PBS, at
37 °C for up to 4 h.2.3. Physicochemical and morphological characterization of PARG NCs
Particle size distribution and PDI were determined by dynamic light
scattering (DLS) and zeta potential was calculated from the electropho-
retic mobility values determined by laser doppler anemometry (LDA).
Both were obtained with a Malvern Zeta-sizer device (NanoZS, ZEN
3600, Malvern Instruments, Worcestershire, UK) equipped with a red
laser light beam (λ= 632.8 nm). To measure the particle size and PDI,
a volume of 50 μL of the formulations was diluted with 950 μL of ultra-
pure water. For the Z-potential measurements, the sample was diluted
with 1 mM KCl solution in the same proportion. The analysis was per-
formed at 25 °C with at least, three different batches and each batch
was analyzed in triplicate. The morphological analysis of the NCs was
carried out in a transmission electron microscope (TEM, CM12, Philips,
Netherlands). The samples were stained with phosphotungstic acid
(2%, w/v) solution and placed on cupper grids with Formvard® for
TEM observation.2.4. Association of insulin to PARG NCs
The AE of insulin to PARG NCs was determined upon separation of
the NCs from the suspending aqueous medium. The analysis was done
by both indirect and direct methods. Briefly, in the indirect method,
2mL of NC formulationwas ultracentrifuged (Beckman Coulter, Optima
L-90K, Brea, USA) at 82,656 g for 1 h at 15 °C, and the amount of free in-
sulin in the undernatant was determined using reverse phase isocratic
HPLC (Agilent, 1100 Series, Santa Clara, USA) method. The phosphoric
acid/sodium perchlorate buffer wasmixed with acetonitrile at different
volume phase ratios, in order to produce two different mobile phases
(93:7 as phase A and 43:57 as phase B), and C18 column (Superspher®
RP-18 endcapped) was used as stationary phase. The AE of insulin in
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AE %ð Þ ¼ Total insulin−Free insulin
Total insulin
X100
where Total insulin is the theoretical total insulin concentration in the
formulation, and Free insulin is the insulin concentration determined
by HPLC. Analysis was done in triplicate.
When using the directmethod, 500 μL of NCs were isolated from the
suspensionmediumby size exclusion chromatographyusing Sephadex-
G50 column. The cream fractions and the transparent aqueous fractions
were collected in microtubes. Insulin was extracted from the NC cream
following the next steps: 1) 100 μL of the cream were vortexed with
100 μL of acetonitrile for 2 min, 2) 100 μL of Triton™ X-100 were
added to the previous mixture and vortexed for 2 min, 3) 700 μL of
0.1% (v/v) of a trifluoroacetic acid (TFA) solutionwere added to themix-
ture and all the components were vortexed. Finally, both the broken
NCs and the transparent aqueous fractions were analyzed by HPLC in
order to determine the amount of insulin associated to the NCs and
also in the suspending medium. Simultaneously, 500 μL of non-isolated
NCs were degraded following the same procedure and the total insulin
concentration was determined by HPLC, by which the gross mass of in-
sulin in 500 μL NC formulation was obtained. The AE of insulin in NCs
was calculated dividing the amount determined in the isolated NC
cream by the amount determined in the non-isolated NCs. Analysis
was done in triplicate.
The final insulin loading (% w/w) was calculated by dividing the
amount of insulin associated (AE × Total Insulin in the formulation) by
the total weight of the NCs. For the calculation of the total weight of
the NCs, 500 μL of the formulation were isolated by ultrafiltration
using 100k Amicon® filters (Merck Millipore, Carrigtwohill, Ireland), a
method that facilitates the re-suspension of NCs without diluting the
sample. TheNC creamwas resuspended to 500 μL and lyophilized solely
in microtubes, which were weighed before adding NC sample and after
freeze drying to assess the solid mass of the cream. The yield of PARG
NCs was calculated by a division of isolated and non-isolated NCs
cream weight after freeze-drying.
2.5. Stability of PARG NCs in simulated intestinal media
The colloidal stability of NCs in simulated intestinal fluids was eval-
uated by analysis of the particle size and PDI by DLS. Additionally, parti-
cle concentration of the sample was monitored by analysis of the light
intensity count rate. To mimic the intestinal environment following
oral delivery, SIF, FaSSIF-V2 (pH 6.5) and FeSSIF-V2, (pH 5.8) were pre-
pared (for composition, see supplementarymaterial on Table 1). FaSSIF-
V2 and FeSSIF-V2 are updated versions of the FaSSIF and FeSSIF media
described in the pharmacopeia, to better mimic the in vivo fasted and
fed state intestinal conditions [28,29]. The study was carried out using
50 μL of NCs that were diluted in 950 μL of simulated intestinal media
in a microtube, and then placed in an incubator at 37 °C (Heidolph In-
struments GmbH & Co. KG, Schwabach, Germany) with a horizontal
shaking at speed 300 rpm. At different time points (0 h, 0.5 h, 1 h, 2 h
and 4 h), 50 μL samples were withdrawn and the particle size, PDI,
and count rate were determined at the different time points using
Malvern Zeta-sizer (Attenuator 6). To exclude the interference of pan-
creatin aggregates in particle size measurements, after incubation of
NCs in FeSSIF-V2, the microtubes were centrifuged at 13,600 g for
5min, so the pancreatin precipitated andwas isolated from the suspen-
sion media. Each analysis was performed by triplicate in three different
batches. The colloidal stability of the NCs under storage condition was
analyzed as follows: different aliquots of the formulation were con-
served at room temperature (around 20 °C). The particle size, PDI and
count rateweremonitored up to 45 days to check the potential destabi-
lization of the formulation. The insulin remaining in the formulation
was also determined.2.6. In vitro release profile of insulin from PARG NCs
The amount of insulin released in vitro upon incubation of PARGNCs
in SIF and FaSSIF-V2media, at 37 °C under horizontal shaking (300 rpm)
was quantified byHPLC. Specifically, aliquots of 0.25mL of insulin-load-
ed NCs were diluted with 1.25 mL of the desired intestinal media and
placed in an incubator. After 0, 2, 3, 3.5 and 4 h, samples were with-
drawn and ultracentrifuged (82,656 g; 4 °C; 1 h). The amount of free in-
sulin and insulin associated to the NCs was evaluated by HPLC upon
treatmentwith Triton™X-100, acetonitrile and 0.1% TFA (samemethod
as the one described in Section 2.4).
2.7. Caco-2 cells culture
Caco-2 cells were grown in DMEM high glucose with L-glutamine
supplemented with 10% heat inactivated fetal bovine serum, 1% Penicil-
lin (100 U/mL), streptomycin (100 μg/mL), and 1% NEAA solution. Cells
were maintained at 37 °C in a humidified incubator supplied with 5%
CO2.
2.8. Toxicity studies on Caco-2 cells
For cytotoxicity evaluation, Caco-2 cells were seeded in 96-well
plates at the density of 10,000 viable cells/well, and incubated for 24 h
to allow the cell attachment. Cells were then incubated with increasing
concentrations of the tested samples, whose colloidal stability of NCs in
cell culture medium has been confirmed in advance. The cytotoxicity of
PARG NCs was determined by measuring the metabolic activity with
neutral reduptake (NRU). Lactate dehydrogenase (LDH)-based cytotox-
icity assaywas also used tomeasure LDH released intomedia fromdam-
aged cells as a biomarker for cellular cytotoxicity and cytolysis. In the
study, the cell culture medium was replaced by the PARG NC (or
nanoemulsion) suspension in cell culture medium at concentration
0.1855, 0.371, 0.742, 1.484, 2.968, 4.452, and 5.936 mg/mL. The plate
of Caco-2 monolayers was transferred to a humid incubator at 37 °C
with 5% CO2. After 2 h incubation, the tested samples were removed.
In neutral red uptake (NRU) assay, treated Caco-2 cells were rinsed
with PBS and then incubated for 3 h at 37 °C with 100 μL of cell culture
mediumcontaining 10%Neutral Red solution. After incubation,medium
was removed and cells rinsed twice with Dulbecco's PBS before adding
Neutral Red Assay solution. Plate was shaken 45 min at room tempera-
ture, and absorbance recorded at 540 nm with Synergy 4 microplate
reader (BioTek Instruments, Inc., Winooski, USA). Before performing
NRU assay, 50 μL of cell culture media were transferred into a new 96-
well plate, mixed with 50 μL of working reagent for LDH detection and
incubated for 20 min at room temperature in the dark. Reaction was
blocked by adding 25 μL of the stop solution, and the amount of pro-
duced formazan was measured recording absorbance at 500 nm with
Synergy 4 microplate reader. The assays were repeated three times in-
dependently, each run as three independent technical replicates. Re-
sults are reported as a percentage of control (treated with cell culture
medium only) and expressed as mean ± standard deviation. The cyto-
toxicity of the PARG polymer solution was evaluated by NRU assay fol-
lowing the same protocol. The tested concentrations were 0.009,
0.017, 0.034, 0.068, 0.137, 0.205, and 0.274 mg/mL, which were equal
to the amounts of PARG polymer involved in the tested PARG NCs con-
centration successively.
2.9. Measurement of the transepithelial resistance (TEER) and insulin
transport across the Caco-2 monolayer
Caco-2 cell monolayers were cultured on tissue-cultured-treated
PET filters (1 μm diameter, 1.1 cm2, Millipore Transwell® 12 well/
plate), andwere used for experiments 21 days after seeding. The evalu-
ation of PARGNCs was performed in Caco-2 cell monolayers for two NC
concentrations: 0.5 mg/mL and 1 mg/mL. The cell culture medium and
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used as controls. The variation in the TEER values for the cell monolayer
integrity assessmentwasmeasuredwith aMillicell-Electrical Resistance
System (Endohm-12,Millipore Corp). Monolayers with a TEER values in
the range of 800–1500Ω cm2were used. Simultaneously, samples were
collected (500 μL) from the receiver compartment and the apical com-
partment 2 h after NC cell monolayer exposure and the insulin concen-
trations were measured using a liquid chromatography - mass
spectrometry. Cell monolayers were gently washed with NaCl 0.9%
and frozen at −80 °C for insulin quantification within the cells. Liquid
chromatography (Shimadzu HPLC system LC 20AD, Japan) with a
150 × 2.1 mm – 5 μm – 300 Å HPLC C8 column (Interchim, France)
was used for the elution of insulin with a gradient method. The mobile
phases A and B were 0.1% formic acid solution and acetonitrile contain-
ing 0.1% formic acid, respectively. Theflow ratewas 0.6mL/min to avoid
pressure rise. 100 μL of the tested sample was treated with 200 μL of
chloroform/methanol/water at 1/1/0.3 and 100 μL of 0.1 M NaOH, and
then 40 μL of analyte was injected onto the column placed in an oven
at 60 °C. The total run time was 13 min. Tandem mass spectrometry
(Quantum ultra) in positive electrospray mode was used for detection.
System control and data processing were carried out using MassLynx
software version 4.1. Spray voltage was 3.0 kV, and sheath and auxiliary
gas pressures were 50 and 15 (arbitrary units), respectively. The in-
source CID energy was fixed at 12 V, and capillary temperature was
350 °C. Tube lens and collision energy valueswere optimized for insulin.
Multiple reactionmonitoringwas used for the detection of the ion tran-
sitions. Themultiple reactionmonitoring transitions for analytes was as
follows: m/z insulin 709.805 N 731.76, m/z insulin 1284.73 N 1104.60.
Analytes were quantified by means of calibration curves using insulin
as internal standard. The standard curves showed linearity for creatine
over a range of 0.025–10 μg mL−1 for insulin. The methodology for
this assay involves reduction with dithiolthreitol 45 mM and alkylation
with 100 mM of iodoacetamide 100 mM of intact insulin for measure-
ment of the free B chain.
2.10. In vivo fluorescence imaging of DiD-loaded PARG NCs
One week before the experiment, the BALB/c mice were placed
on a low manganese diet to reduce autofluorescence. The abdomi-
nal fur was removed by depilation. Prior to the experiment, the an-
imals were fasted for 24 h, and then 200 μL of DiD loaded PARG NCs
(NC 22 mg/mL, DiD 10 μg/mL, n = 4) or free DiD solution at the
same concentration were administered to mice by oral gavage
(n = 2). In vivo biodistribution was performed by total body scan-
ning at different time points (0, 1, 3, 6, 24 h) on isoflurane/oxygen
anesthetized animals, using a MX2 scanner (ART, Montreal, Cana-
da). Confocal microscopy was used to further examine the interac-
tion of PARG NCs with the intestinal epithelium. In control group,
the mice were treated with free DiD instead of DiD-loaded PARG
NCs. The intestines were dissected after treatment, washed with
PBS and fixed in 4% PFA for 3 to 4 h at 4 °C. Afterwards, they were
treated and stored at −80 °C for cryostate processing. Samples
were then cut into 10 μm thick cryoslices using a Leica CM 1850
CM cryostat and transferred to slides (SuperFrost Plus, Thermo Sci-
entific). Confocal images were acquired with Leica TCS SP5 II mi-
croscope and further processed using ImageJ software.
2.11. In vivo bioactivity of encapsulated insulin
All animal experiments were reviewed and approved by the
ethics committee of the University of Santiago de Compostela (pro-
cedures from Prof. Carlos Diéguez, 1500AE/12 / FUN01/FIS02/
CDG3) according to the European and Spanish regulations for the
use of animals in animal studies; performed therefore in compli-
ance with the Directive 2010/63/EU of the European Parliament
and Council of 22nd September 2010 on the protection of animalsused for scientific purposes; Spain Royal Decree 1201/2005, of Oc-
tober 10th, on the protection of animals used for experimental and
other scientific purposes and under the Royal Decree 296/2008 of
Spain 30th December on the protection of animals used for exper-
imental and other scientific purposes, including teaching. Male
Sprague-Dawley rats (247–272 g) were obtained from the Central
Animals House of the University of Santiago de Compostela
(Spain). The animals were fasted for 4 h prior to the experiments,
with free access to water, and kept conscious for the duration of
the experiment. Only those with initial glucose level over
65 mg/dL were selected for the study. A dose of insulin loaded
PARG NCs (1 IU/kg) in a volume to weight ratio of 1 μL: 1 g rat
was administered subcutaneously. As control, plain insulin solu-
tion was administered to the animals following the same proce-
dure at the same dosage. Blood samples were collected from the
tail vein 30 min prior to the subcutaneous administration to estab-
lish the baseline blood glucose level. At time point of 0.5, 1, 1.5, 2, 3,
4, 5, 6, 7, and 8 h after administration, blood samples were collect-
ed to monitor the glucose level change following the PARG NCs or
insulin administration. The glucose level was measured using a
glucometer (Glucocard™ G+ meter, Arkray Factory, Japan).
2.12. In vivo efficacy studies in non-diabetic rats
For the in vivo evaluation of the hypoglycemic response, Male
Sprague-Dawley rats (240–290 g) were obtained from the Central Ani-
malsHouse of theUniversity of Santiago deCompostela (Spain). The an-
imals were fasted for 4 h prior to the experiments, with free access to
water, and kept conscious for the duration of the experiment. Only
those with initial glucose level over 65 mg/dL were selected for the
study. PARG NCs were administered intraduodenally (with or without
3% sodium glycocholate, SGC, in NC suspension) at an insulin dosage
of 50 IU/kg body weight in a volume to weight ratio of 1 μL: 1 g rat,
through a cannula inserted by surgery 1 week before the experiment.
The animals used as controlwere administered blank PARGNCswithout
insulin loading, following the same procedure. Additionally, an insulin
solution in saline was subcutaneously injected at a dose of 1 IU/kg in a
volume to weight ratio of 1 μL: 1 g rat to a different group. Blood sam-
ples were collected from the tail vein 30 min prior to the oral adminis-
tration in order to establish the baseline blood glucose level. At time
point of 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 h after dosing, the blood samples
were collected to monitor the glucose level change following the PARG
NC or insulin administration. The glucose level was measured with a
glucometer. For the control study and to test the mixability of PARG
NCs and SIF, the purified and highly concentrated NCs were resuspend-
ed in water or sodium glycocholate (SGC) solution to 3% (w/v) SGC in
the final formulation. Both were transferred to a glass vial that
contained SIF, at a NC to SIF volume ratio proportional to the in vivo ef-
ficacy study condition with fasted state rats (~300 μL formulation in
3.2 mL SIF).
3. Results and discussion
The main objective of this work was to design, develop and
characterize a peptide nanocarrier with a potential to confront all
the barriers associated to the oral modality of administration. Be-
cause of our experience and the positive results we had obtained
with chitosan NCs [13,14], we decided to adopt and optimize this
NCs technology in order to obtain a NC prototype that could fulfill
the requirements associated to the oral administration. As indicat-
ed in the introduction, the tailored properties were: i) capacity to
load and control the release of the associated peptide; ii) stability
in the intestinal fluids; iii) capacity to diffuse across the mucus
layer; iv) capacity to interact with the intestinal epithelium and fa-
cilitate the transport of the associated peptide.
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insulin
A schematic representation highlighting the components and the or-
ganization within the NCs is shown in Fig. 1. These components and
their appropriate concentrations were selected upon a thoughtful
screening, as illustrated in Fig. 2. First, we explored the utility of two dif-
ferent oils, oleic acid and Miglyol® 812N, the last one being the most
commonly used to formulate NCs [14,15,30–33], and fixed the rest of
the formulation parameters: 0.4% (w/v) surfactant Labrasol®, and 0.1%
(w/v) PARG. According to our results, the size of the particles and
their polydispersity were smaller when using oleic acid instead of
Miglyol® 812 N (233 nm vs. 310 nm; PDI 0.14 vs. 0.39 for oleic acid
and Miglyol®). This size reduction of the formulation could be due to
the chemical architecture of each oil matrix (C18 vs. C8/C10 triglycer-
ides) and also to the higher viscosity of the oleic acid in comparison
with Miglyol® 812N [34–36]. Based on this and also on its penetration
enhancing properties [37,38], oleic acid was selected as a critical com-
ponent of the NCs for further optimization.
In the second optimization stage, we analyzed simultaneously the
effect of three different surfactants (Span® 80, Tween® 80 and
Labrasol®) and PARG concentration on the physicochemical properties
of the resulting nanocapsules. The results, shown in Fig. 3, indicate that
the nanoemulsions prepared with the three surfactants have a negative
charge ranging from−40 to−70mV and a size of 200–300 nm. While
Span® 80 and Labrasol® displayed similar Z-potential, around−70mV
(see Fig. 3), incorporation of Tween®80 to the formulation led to a clear
reduction of the superficial charge of the nanoemulsion (around
−40 mV, see Fig. 3). Considering the molecular structure of these
three surfactants (see Fig. 4), Tween®80,with clearly differentiated hy-
drophobic/PEG domains can incorporate its hydrophobic moiety into
the oil phase and extend its PEG arms towards the aqueous phase.
This result in the displacement of the nanoemulsion slippery plane
and then, in a reduction of the Z-potential magnitude [39]. However,
upon addition of PARG to the NCs fabrication process, significant chang-
es in size and zeta potential were observed. First, the nanosystems con-
taining Span® 80 and Labrasol® exhibited an inversion of Z-potential
from highly negative to positive, which should be attributed to the at-
tachment of PARG, and hence to the formation of the NCs. This efficient
attachment was only observed for concentrations of PARG of 1–
2 mg/mL, whereas a lower concentration (0.5 mg/mL) only led to theFig. 1. Structural illustration of PAdestabilization of the nanosystem (size in the μm range and Z-potential
close to cero). In contrast, in the case of Tween® 80, no change in size
and aminor inversion in the zeta potential were observed. Consequent-
ly, we concluded that both the type of surfactant and the concentration
of PARG play a critical role in the formation of the nanocapsular
structure.
These observations could be explained by the different structure of
these three surfactants. Tween® 80 contains hydrophobic domains
and hydrophilic PEG sections, while Span® 80 is more hydrophobic,
exhibiting only –OH groups as hydrophilic entities. On the other hand,
Labrasol® is amixture of glyceridesmodifiedwith -PEG-C8/10moieties.
Considering this, we could speculate that the PEG moieties of Tween®
80 would be projected towards the surface of the nanocapsules, thus,
hampering the adsorption of the PARG molecules. In contrast, the ab-
sence of a PEG shell in Span® 80 and Labrasol®- containing prototypes
might facilitate the incorporation of PARG onto the O/W interface. To il-
lustrate this explanation, Fig. 4 includes the schematic representation of
the arrangement or these three non-ionic surfactants on the O/W inter-
face of the systems.
In the next step, SDC was employed as a co-surfactant. The charac-
terization of the resulting prototype indicated that the size of the SDC-
containing NCs was reduced and the zeta potential could be modulated
from +12 mV to −30 mV, depending on the balance between PARG
and SDC. Despite the encouraging properties of the composition de-
scribed above, theseNCs turned out to be unstable after a fewdays' stor-
age. In order to enhance the colloidal stability during storage, we added
poloxamer 188 as a PEGylated protective shell. This shield was also ex-
pected to, firstly, increase the stability of the NCs when interacting with
intestinal lipids and enzymes [34], and secondly, facilitate the diffusion
of the NCs across the mucus [40,41].
Following the above formulation optimization process, we selected
the specific ingredients as illustrated in Fig. 1. This specific prototype ex-
hibited a hydrodynamic mean size of around 200 nm, low PDI and a
negative Z-potential (shown in Table 1). In TEM analysis, the NCs
displayed a smaller size than the one calculated by DLS. This could be
due to the shrinking of the NCs during the drying process. The images
also showed that the NCs have a spherical shape (Fig. 5).
The insulin incorporation into these NCswas expected to depend on
the electrostatic and hydrophobic interactions between this drug mole-
cule and various NC components. Such interactions are obviously asso-




















Fig. 2. Flow diagram that outlines the rational design process of PARG NCs.
9Z. Niu et al. / Journal of Controlled Release 263 (2017) 4–17isoelectric point (IP). In order to expose insulin molecules to different
pH values, we adjusted the aqueous phase to different pH values
which had an impact on the final pH of the formulations. As shown in
Fig. 6, when the final pH of the formulation was close to the insulin IP
(IP = 5.49), it was possible to reach an AE close to 80%. However, at
pH values farther from this IP (either higher or lower), the insulin AE
was clearly reduced. The increased on the insulin entrapped at the pH
close to its IP could be attributed to the predominance of hydrophobic
interaction between the hydrophobic domains of this peptide with the
components of the NC core, and the reduced affinity of insulin towards
the aqueous phase.
Given the importance of pHon the insulin encapsulation process, we
explored the possibility of using a buffer as the aqueous phase in order
to ensure a final formulation pH close to 5.4. Among the different buffer
systems investigated, we found that the use of 20mMacetate buffer led
to the formation of NCswith a size of 185±6nm, a low PDI and anAE ofFig. 3. Influence of surfactant type and PARG concentration on the physicochemical properti
Mean ± S.D., n = 3.88 ± 5% (Table 1, determined by direct method and confirmed by indi-
rect methods described in the methodology section). Taking into ac-
count that the production yield of the NCs is 74.21 ± 0.26% (w/w), the
final insulin loading was 1.49% (w/w), a loading that was acceptable
for subsequent studies.
3.2. Stability of PARG NCs in simulated biological media
We hypothesized that the success of the formulationwould depend,
at least in part, on its capacity to maintain its physicochemical proper-
ties under physiological conditions. Fig. 7 shows the particle size evolu-
tion of insulin loaded-PARG NCs in SIF (pH 6.8), FaSSIF-V2 (with bile
salts, pH 6.5) and FeSSIF-V2 (with enzymes and bile salts, pH 5.8)
media during 4 h. The results indicate that independent of the simulated
intestinal media composition, the PARG NCs size (originally 178 nm)
remained quite stable during the incubation time. Accordingly, thees of blank formulations. When PARG concentration is 0, the system is a nanoemulsion.
Fig. 4. Chemical structure and schematic representation of the arrangement of Span® 80,
Tween® 80 and Labrasol®, in the O/W interface of the nanostructure. Red lines represent
the hydrophobic moieties, while blue represent the hydrophilic fragments (dashed lines
for PEG and spheres for –OH groups). Green spheres represent the linkers of each
molecule.
10 Z. Niu et al. / Journal of Controlled Release 263 (2017) 4–17count rate, providing an indication of the particle number in suspension,
was hardly altered during the experiment [42]. This stability in biologi-
cally relevant media containing enzymes and bile salts has been attrib-
uted to the adequate protection of both the shell and our rational design
[34]. A small decrease in particle size was observed upon dilution of the
NCs in FeSSIF-V2, which could be attributed to the interference of the
FeSSIF-V2 medium with the size measurement technique.
3.3. Colloidal stability of insulin-loaded PARG NCs during storage
Insulin-loaded PARGNCswere stored, as a suspension, at room tem-
perature (~25 °C). The particle size and count rateweremonitored up to
45 days (supporting materials Fig. S1), and the results showed that
these PARGNCs remained stable over this period of time. In addition, in-
sulin content in these NCs was determined at 0, 1, 3, and 15 days, and
the insulin remaining unmodified. These positive preliminary stability
data are in good agreement with the stabilization strategy defined in
the formulation process of NCs.Table 1
Physicochemical properties of insulin-loaded PARG NCs and blank PARG NCs, showing influenc
sulin association efficiency. Mean ± S.D., n ≥ 3.




Blank NCs 10.8 5–6
5.5 (buffer) 5.2–5.43.4. In vitro release of insulin from PARG NCs
The release of insulin from PARG NCs was studied in different simu-
lated intestinal media, e.g. in SIF and FaSSIF-V2 (SIF plus bile salts),
which mimic the fasted state of the animals in the in vivo assay. The re-
sults obtained in SIF medium showed a negligible peptide release (data
not shown). In contrast, in FaSSIF-V2 medium, 21% peptide release was
evidenced at time 0 h, followed by a continuous release of up to 54% at
4 h (Fig. 8). The rest of insulin could be recovered from the NCs, upon
their digestion. The 21% burst release was likely due to the immediate
release of insulin molecules located near the surface of the
nanocapsules. This profile also suggests that the presence of bile salts
and surfactants in FaSSIF-V2 releasemedium triggered the release of in-
sulin. Because the NCs were stable in this medium in terms of size
(Section 3.2), we hypothesize that the bile salts and surfactants could
be responsible for the disassociation of insulin exposed to the surface
in the PARG/surfactants shell [43–45]. This sustained release profile is
supposed to be of interest for the intestinal delivery of insulin. Indeed,
the NCs are supposed to reach the intestinal epithelium in the duode-
num-jejunum segments in the first hours upon oral administration.
Once there, the NCs would provide a continuous delivery of the associ-
ated insulin. Eventually, after a few hours, the NCs would disintegrate
and release their content.
3.5. Toxicity of PARG NCs on Caco-2 cells
The cytotoxicity of insulin loaded PARG NCs was evaluated in the
Caco-2 model using the LDH and NRU assays. The results of the DHL
assay shown in Fig. 9A, indicate that PARG NCs induced a dose-depen-
dent toxicity after a 2 h incubation. LDH release from the damaged
cells was observed when the concentration of NCs tested was
1.48 mg/mL or higher. Very similar results were observed when using
the NRU assay (Fig. 9B). In this case, the cytotoxicity of PARG NCs was
compared with that of the control nanoemulsion (same constituents
as the NCs except PARG). The conclusion from these data was that the
toxicity of the NC andNEwas very similar, showing a significant toxicity
only at the concentration of 1.48 mg/mL. On the other hand, the results
shown in Fig. 9C indicate that the toxicity of the free PARG polymer was
superior to that of the NCs and nanoemulsions. However, considering
the limited amount of PARG polymer involved in NCs (0.03 mg/mL in
each 0.74 mg/mL NCs), the conclusion was that PARG does not contrib-
ute significantly to the toxicity of the NCs. Overall, the toxicity profile
observed for PARGNCs is similar to the one observed for similar compo-
sitions [17] and could be attributed, mainly, to the penetration enhanc-
ing effect of the NC components when interacting with the enterocytes
[38,46].
3.6. Effect on the transepithelial electrical resistance (TEER)
Some cationic polymers, among them chitosan [13,47], are well-
known for their capacity to open the intercellular tight junctions (TJs),
thereby altering the transepithelial resistance and facilitating the
paracellular transport of hydrophilic drugs. Recent reports from our
own group [17] and others [46] have also claimed this functionality
for PARG. In this study, we evaluated the effect of PARG NCs on the
TEER of the Caco-2 monolayer and used a PARG solution as control.e of pH/salt content (acetate buffer) of the external aqueous phase (PARG solution) on in-
Size (nm) PDI Z-pot (mV) AE (%)
213 ± 27 0.1 −3 ± 4 b10
178 ± 20 0.1 −30 ± 2 81 ± 6
185 ± 6 0.2 −24 ± 3 88 ± 5
189 ± 5 0.1 −33 ± 3 –
177 ± 5 0.1 −23 ± 2 –
Fig. 5. Transmission electron micrographs of the PARG NC.
11Z. Niu et al. / Journal of Controlled Release 263 (2017) 4–17The results indicated that the TEER value of Caco-2 cellswas not affected
at a PARG NC concentration of 0.5 mg/mL (data not shown). However,
consistent with our previous finding, when the concentration was in-
creased up to 1mg/mL, both PARGNCs and the free PARG induced a sig-
nificant TEER decrease (15% and 38%, respectively) after a 2-h
incubation period (Fig. 10). Interestingly, after removing PARG NCs, a
significant TEER recovery was observed at 24 h, thus proving the tran-
sient opening of the TJs. In contrast, the TEER value was not recovered
upon exposure to the free polymer. Overall, this study confirmed the ca-
pacity of PARG polymer to open the intercellular TJs [46], and showed
that by incorporating this polymer to the PARG NC shell, it is possible
to modulate the permeation enhancing capacity of the polymer. This
may also suggest that the toxicity observed on the Caco-2 cells could
be transitory.
3.7. Capacity of PARG NCs to enhance the transport of insulin
As shown in the previous section, PARG NCs are able to alter the
TEER in a transientmanner. In addition, in a previous study,we reported
the capacity of PARG NCswith a different oil/surfactants composition to
enter the Caco-2monolayer [17]. Based on these results, our next objec-
tive was to analyze in vitro if the PARG formulation rationally designed
in this study could work as an insulin carrier. The results shown in Fig.
11A and B indicate that, after a 2-h incubation period, 3.54 ± 0.27% of
insulin associated to the NCs (1 mg/mL) had been transferred to the
basolateral compartment and 1.29 ± 0.53% remained associated to the
monolayer. In addition, a significant transport was also observed for
the physical mixture of PARG and insulin (2.73 ± 0.32% transportedFig. 6. Influence of pH of the PARG NC suspension on insulin association efficiency.
Mean ± S.D., n = 3.and 0.67 ± 0.08%, retained in the cells) (Fig. 11A). In order to have an
idea about the extent of this transport, we have compared these values
with the only ones reported in the literature so far,whichwere obtained
with chitosan-based nanoparticles, a nanocarrier extensively investigat-
ed for oral insulin administration [48]. According to this previous report,
insulin associated to chitosan nanoparticles was transported up to
~1.3% across the Caco-2 monolayer within a 2 h time frame. Based on
these data, we could conclude that the transport attained with PARG
nanocapsules is superior than the one observed for chitosan nanoparti-
cles. The interpretation of the positive data obtained for PARGNCs could
be as follow. First, taking into account the transient changes in the TEER
and the transport observed for insulin physically mixed with PARG, we
could hypothesize that the paracellular pathway has contributed to the
enhanced insulin transport. On the other hand, given that insulin pene-
trationwas higher for PARG nanocapsules than for the physical mixture
PARG and insulin, we could speculate about the potential intracellular
uptake of PARG nanocapsules. The higher insulin transport achieved
with PARG NCs, when compared to free PARG, could be explained by
the co-localization of the peptide in association with PARG and other
permeation enhancers present in the formulation. In fact, the oleic
acid and bile salts present in the NCs core are known to increase the flu-
idity of cell membrane, and enhance the membrane permeability [18,
20,38,49,50].
3.8. In vivo fluorescence imaging of DiD-loaded PARG NCs
In order to have an in vivo preliminary estimation of the interaction
of PARGNCs with the intestinal tract, we traced fluorescent DiD-labeledFig. 7. Evolution of the particle size of PARG NCs upon incubation in SIF, FaSSIF-V2 and
FeSSIF-V2 media at 37 °C. Attenuator of DLS fixed to 6. Mean ± S.D., n = 3. Original size
of the formulation: 178 nm.
Fig. 8. In vitro insulin release profile of PARG NCs in FaSSIF-V2 medium. The amount of
released insulin was calculated by determining the insulin amount remained associated
to the NCs at the specific time points.
Fig. 10. TEER assay on Caco-2 cell monolayers exposed to PARG NCs (1mg/mL, containing
0.045 mg/mL PARG and 0.014 mg/mL insulin) or to PARG polymer
(0.045 mg/mL) + insulin (0.014 mg/mL). 2 h after exposure and 24 h after removal of
the prototypes from the cells. Data expressed as mean ± SD, n = 3. Changes were
considered statistically significant at p b 0.05: *p b 0.05 compared to non-treated control
group; ***p b 0.05 compared to PARG NC group.
12 Z. Niu et al. / Journal of Controlled Release 263 (2017) 4–17PARGNCs after oral administration tomice. The results obtained for rep-
resentative rats are shown in Fig. 12. The bioluminescent image (Fig.
12A, acquired by the Optix Optiview™, ART, Montreal, Canada) shows
the biodistribution of PARG NCs or free DiD dye following its adminis-
tration by oral gavage to mice, and the histogram on (Fig. 12B) shows
the mean of total photons emitted from the regions of interest (ROI,
the rat body). The images suggest that both PARG NCs and free DiD
dye are confined in the gastro-intestinal tract for up to 24 h. The associ-
ation of free DiD to mucosa could be explained by the affinity of thisFig. 9. Cytotoxicity of PARGNCs and the control groups (non-PARG coated nanoemulsion and PA
determined by LDH assay; (B) Cytotoxicity of PARG NCs and control nanoemulsion determined
n = 3.amphiphilic dye to cell membrane. In fact, this dye is primarily used
for labeling membranes. However, the analysis of florescence intensity
gave some preliminary evidence of the greater retention of PARG NCs
as compared to free dye.
A more detailed in vivo analysis involving dissection of the mice in-
testines (duodenum) at 1 h, 3 h, and 24 h after oral administration ofRG polymer solution) in Caco-2 cell line after 2 h incubation. (A) Cytotoxicity of PARGNCs
by NRU assay; (C) Cytotoxicity of PARG polymers determined by NRU assay. Mean± S.D.,
Fig. 11.Apical to basolateral transport of insulin across the Caco-2 cellmonolayer under 37 °C, after 2 h incubationwith insulin loaded PARGNCs (1mg/mL, containing 0.045mg/mL PARG
and 0.014 mg/mL insulin) or PARG polymer (0.045 mg/mL) + insulin (0.014 mg/mL). Data expressed as mean ± SD, n = 3. Changes are considered statistically significant at p b 0.05,
evaluated by ANOVA following Tuke's multiple comparison post hoc test (SigmaPlot SyStat Software Inc., San Joes, CA).
Fig. 12. (A) Fluorescence images of representativemice at 0, 1, 3, 6, and 24h following oral administration of DiD labeled PARGNCs (up) and freeDiD (down) dye and (B) themean of total
photons ± S.D. emitted from regions of interest around GIT. n = 4 for DiD-loaded PARG NC group, n = 2 for free DiD control group.
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14 Z. Niu et al. / Journal of Controlled Release 263 (2017) 4–17PARG NCs was performed. The results presented in Fig. 13 show an in-
tense fluorescence signal overarching the duodenum villi 1 h after ga-
vage. These images suggest that once PARG NCs reach the intestinal
tract, they may diffuse through the mucus layer that covers the villi
and reach the enterocytes. The fluorescence intensity observed within
the duodenum region decreased significantly at 3 h after treatment,
suggesting that the nanocapsules have moved away to lower intestinal
regions (small and large intestine) or though the submucosal space. De-
spite the control experiments showing the absence of dye release from
the NCs, we cannot discard the possibility that, under the in vivo condi-
tions, the DiD dye could be released and diffuse through the body.
3.9. Bioactivity of encapsulated insulin and in vivo efficacy of PARG NCs
It is well known in the biotechnology field that the formulation pro-
cess may result in the inactivation of labile macromolecules, such as
peptides [51]. That is why; we thought it was important to analyze
the bioactivity of peptides following their subcutaneous (s.c.) adminis-
tration before studying the in vivo efficacy of the oral formulation.
Thus, insulin-loaded PARG NCs were administered subcutaneously to
fasted (4 h) healthy rats, using an insulin saline solution as control.
The blood glucose level was normalized taking the 0 h mean glucose
baseline value as 100%. As shown in Fig. 14, following the s.c. injection,
both, the insulin solution and insulin-loaded NCs, exhibited a similar
profile, where a drastic decrease in the glucose level was observed atFig. 13. Confocal images showing the interaction of DiD-loaded PARG NCs with mice duode
objectives).0.5 h and the normal levels were recovered at 3 h. From these results,
it can be concluded that the mild conditions of the formulation process
have not affected the bioactivity of the insulin.
Subsequently, an in vivo efficacy study was performed following
intra-duodenal (50 IU/kg) administration to conscious healthy rats
after 4 h fasting. Based on the results of a control experiment that
showed that purified PARG NCs, highly deprived of surfactants, could
have miscibility problems, the efficacy of PARG NCs was assessed in
the absence or presence of SGC (3%, w/v). The colloidal stability of
PARG NCs of the nanocapsuels was preserved in this medium and the
dispersibility was greatly enhanced (Fig. 15).
The results show that the administration of insulin-loaded PARGNCs
led to a significant decrease in the blood glucose levels, which lasted for
less than two hours (Fig. 16). However, as expected, the co-administra-
tion of the NCs with SGC led to a prolongation of the hypoglycemic re-
sponse (for up to 5 h). In addition to the well-known penetrating
enhancing capacity of bile salts, the prolongation of the hypoglycemic
response could bemost probably associated to the improved dispersion
of the formulation along the intestinal tract. Overall, as shown in Table 2,
the apparent pharmacological bioavailability was 0.73% and 2.14% and
the Tmax extended from 1 h to 6 h, in the absence or presence of SGC.
Beyond the improved behavior of PARG NCs in the presence of SGC,
the overall performance of the formulationmust be consideredmodest.
In principle, based on the rational design of the formulation and positive
in vitro properties of same, notably, the observed preservation of thenal tissue, 0 h, 1 h, 3 h, and 24 h after oral administration (20× magnification with air
Fig. 14. Standardized hypoglycemic effect in healthy rats following subcutaneous
administration of insulin-loaded PARG NCs and insulin saline solution at 1 IU/kg. Data
represents the mean ± S.E., n = 8 for both groups.
Fig. 16. Standardized hypoglycemic effect in healthy rats following intra-duodenal (with
and without sodium glycocholate, SGC) administration of insulin-loaded PARG NCs at
50 IU/kg and blank PARG NCs as placebo. Data represents the mean ± S.E., n = 8 for
insulin-loaded PARG NC groups and n = 7 for placebo.
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the intestinal media and the remarkable capacity of this formulation to
promote the transport of insulin across a Caco-2 cells monolayer (Fig.
11), we expected a more significant response for this formulation. Our
hypothesis to explain thismodest efficacy is that, in the in vivo situation
the NCs are highly diluted and, hence, their interaction with the epithe-
lium maybe restricted. It is also possible that the in vitro assays and/or
the in vivo experimental conditions used in the reported studies have
a limited predictive value of the performance of these formulations. In
this regard, it should be taken into account that, in agreement with
our results, all the data reported so far using normoglycemic rats are
very modest [30,52]. Most of the highly positive responses described
until now have been achieved in diabetic rats or using anaesthetic
drugs, which are known to alter the absorption process [53,54]. Indeed,
when using the normal rat as model, the exogenous uptake of insulin
may suppress the endogenous secretion of insulin by β-cells, leading
to a milder hypoglycemic response [30]. On the contrary, the diabetic
animals are over-sensitive to insulin because of the pancreas beta cell
deficiency. In conclusion, the interpretation of these in vivo data should
be evaluated cautiously, and larger animal models, i.e. pig model, will
need to be taken into consideration for a subsequent assessment of
the formulations we have developed.
From the studies performed so far, we conclude that the rational de-
velopment of oral peptide delivery formulations and the translation of
the in vitro data into the in vivo situation possess significant difficulties.
However, we expect that the information reported here will helpFig. 15. Dispersibility of DiD-loaded blank PARG NCs in SIF (A) without and (B) with 3% (w/v)
mixing NCs and SIF without shaking.identify the critical steps to be considered in the design of such formu-
lations. Further work on PARG formulations with the aim of incorporat-
ing the NCs in a final dosage form (enteric capsules) is expected to
provide more elements to assess the performance of this new
formulation.4. Conclusion
In this work, we report the rational design of NCs consisting of
an oily core made of penetration enhancers (oleic acid and SDC)
and a polymer shell made of PARG, a polymer that is known for
its ability to interact and increase the permeability of the cell mem-
branes. The hypothesis behind this design was that the combina-
tion of lipids and penetration enhancers in the form of
nanostructures would reinforce the capacity of the penetration en-
hancers to increase insulin transport. Our results clearly show that
the NCs not only inherited the permeation enhancing properties of
these biomaterials, but also allowed for a significant higher insulin
transport across the Caco-2 monolayer when compared with the
free PARG. In vivo studies indicated that PARG NCs could facilitate
the interaction of both the peptide and the penetration enhancers
with the intestinal epithelium, resulting in an overall increase on
the peptide absorption. Further studies in large animal models
will help assessing the value of this technology for oral peptide
delivery.sodium glycocholate (SGC) in the NCs suspension medium. Photos were taken 1 min after
Table 2
Parameters for plasma glucose levels and relative pharmacological bioavailability of insu-
lin-loaded PARG NCs as compared to subcutaneously injected free insulin solution. Data
expressed asmean±S.E., n=8 for all the groups except for intra-duodenally administrat-
ed PARG NCs with SGC (n = 7).
Formulations Dose (IU/kg) Cmin (%) Tmin (h) AAC PA (%)
s.c. Insulin 1 41 ± 5.8 0.5 194.7 100
s.c. NCs 1 48 ± 6.9 1 171.6 88.2
Intra-duodenal NCs 50 80 ± 13.4 1 70.9 0.73
Intra-duodenal NCs with 3% SGC 50 64 ± 14.3 6 208.4 2.14
Cmin: minimum plasma glucose concentration (% of initial), Tmin: time to Cmin.
AAC: area above the plasma glucose level time curves.
PA: relative pharmacological bioavailability, based on AAC for s.c. administration.
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